Obvious now that these investments are starting to give back good returns and so hence the dividend payment, you wouldn’t be doing that if they weren’t hundred percent confident in high cash revenues in the near future.
I ext divided payments coming regularly as cash flow increases.
Good to see anyway.
I’ll also be using my £5k dividend and buying more shares,
The share buyback is good thing as less shares available the higher any future dividend payments will be.
That’s fair enough but don’t you think the sp will increase rapidly especially next week as we move closer to ex dividend date on the 25th April,
1p is a big payday for all who are in so as I see it they are overflowing with cash and expecting higher revenues in the near term and its rare to see . So opportunity knocks and enjoy a company doi very well and will to share the excess cash to us all.
No question in my enlarged investment today that it’s one of my favourite investments.
This will be over 3p next week without a doubt imo.
Dyor and all the best.
Good to see a company doing very well and having excess cash reserves, also I like the fact that the board are keen to share the wealth with it’s shareholders,
Very impressed with this company and glad I bought in today.
Atb.
So will increase towards Dividend day and how I read the rns today it’s very like there’ll be many more to follow.
The company spilling over with cash flow so it has to go somewhere and so share buybacks and dividend is the best way and very pleasing for shareholders.
Sp should be a lot higher imho.
I’m very pleased that we’re moving into all possible areas to generate future revenues ,
I also love the move into the veterinary sector and potential huge revenue returns in the near term.
Very interesting proactive one to one with investors presentation.
To be fair they’re doing exactly what they intended to do this year and more.
Great listen.
https://www.google.com/search?q=proactive+investor+fusion+antibodies+plc&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#fpstate=ive&vld=cid:14b5e405,vid:IAvbf90GgvQ,st:0
Credit
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the receipt of an R&D tax credit from HMRC in respect of the financial year ended 31 March 2023, relating to work performed on the development and optimization of the OptiMAL® platform, as well as other R&D projects in bioinformatics, antigen design and cell culture. The value of the tax credit is in line with expectations at almost £280k, which reflects the Company's continued investment in R&D projects that maintain Fusion at the forefront of technology in the antibody market. The technologies have been well received by partners and potential partners with the OptiMAL® platform notably undergoing validation through an agreement with the National Cancer Institute in the USA. Fusion will maximise the impact of the tax credit with the generation of revenue streams from the R&D projects that were supported.
Adrian Kinkaid, CEO of Fusion, said: "The R&D tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion. We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."
Just the beginning of the turnaround and already this year we’ve seen two contracts and a collaboration , partnership with the NCI, National Cancer institute in the US.
Some going in Less than three months.
This year is going to be transformational for the company and for us shareholders .
Revenue will follow not far behind.
Strong buy 100 percent.
Any of these?
Something big as they stated it’s a leading global provider of antibodies.
https://blog.citeab.com/who-are-the-leading-research-antibody-market-suppliers/